A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naive Patients With Premenopausal Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 23 May 2016
At a glance
- Drugs Leuprorelin (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics; Registrational
- Sponsors Takeda
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
- 28 Sep 2015 According to a media release, Takeda has obtained a New Drug Application approval of Leuplin PRO for injection kit 22.5 mg, based on the results from this and another phase II trial.
- 04 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.